At Sanofi we continue the successful course of our long tradition that involves some of the most significant achievements of the 19th and 20th centuries.

The strategy of Sanofi is based on three key principles: accelerating innovation in Research & Development, seizing growth opportunities and adapting the company for future challenges and opportunities. By placing patients at the heart of our strategy, we are able to serve them in the best possible way.

With presence in 100 countries and more than 110,000 employees around the world, we work tirelessly to improve access to medicines and healthcare, to make a difference to people’s lives every day and transform scientific innovations into therapeutic solutions for patients.

We implement a new Research & Development model, which creates deeper interaction between clinic and fundamental research, so as to become more efficient in discovering new treatments. In order that the human right to health becomes a reality, we develop programs to improve access to medicines for people in developing countries, we strive to reduce health inequalities through the Sanofi ESPOIR Foundation and we are committed to protect the safety of patients by fighting against counterfeit medicines.

Sanofi, an integrated global healthcare leader, has core strengths in the field of health care with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme, through which Sanofi enhanced its specialized expertise in biotechnology and rare diseases. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Greece, responding to the emerging need for rationalizing pharmaceutical expenditure, offers generic medicines in a wide range of therapeutic areas, such as internal medicine, cardiology, central nervous system, diabetes, etc.